International Journal of Pharmaceutical Compounding

A subscription to IJPC includes a print copy delivered by postal mail and on-line access to electronic PDF copies of your subscribed issues.

LEARN MORE

PostScription: It Is Not Just What You Say…But How You Say It!

Author(s): Reed-Kane Dana

Issue: Jul/Aug 2008 - Hormone Replacement Therapy
View All Articles in Issue

Page(s): 375

PostScription: It Is Not Just What You Say…But How You Say It! Page 1

Download in electronic PDF format for $75

Abstract:

Related Keywords: Dana Reed-Kane, PharmD, FIACP, FACA, NFPPhC, FCP, bioidentical hormone replacement therapy, communication, drug safety, patient education, U.S. Food and Drug Administration, FDA, estriol, BHRT

Related Categories: HRT, LEGAL, PROFESSIONAL ISSUES

Printer-Friendly Version

Title/Author (Click for Abstract / Details / Purchase)	Issue/Page View/Buy
Related Articles from IJPC
PostScription: It Is Not Just What You Say…But How You Say It! Reed-Kane Dana	Jul/Aug 2008 Pg. 375
The Science Behind Hormone Replacement Therapy, Part 1 Wepfer Scott T	Nov/Dec 2001 Pg. 462-464
Patient Satisfaction with Pharmacist Intervention and Consultation in Hormone Replacement Therapy: An Update Hu Fei-Shu, Reed-Kane Dana, Draugalis JoLaine R	May/Jun 2006 Pg. 187-192
PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs Allen Loyd V Jr	Sep/Oct 2017 Pg. 356
Bioidentical Hormone Replacement Therapy, Part 3, A Review of Wepfer Scott T	Mar/Apr 2002 Pg. 142-146
Finally: A Final U.S. Food and Drug Administration Memorandum of Understanding, but It's Flawed Brunner Scott	Jul/Aug 2020 Pg. 296-297
Efficacy and Tolerability of Compounded Bioidentical Hormone Replacement Therapy Vigesaa Kristy A, Downhour Nathan P, Chui Michelle A, Cappellini Linda, Musil John D, McCallian Dennis J	Jul/Aug 2004 Pg. 313-319
Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines Allen Loyd V Jr	Jul/Aug 2016 Pg. 351 View Sample
Menopausal Women's Access Path to Bioidentical Hormone Replacement Therapy: An Exploratory Study Moro Doris, Young Wendy, Stein Richard, Isaac Winston, Goodman Deborah	Mar/Apr 2010 Pg. 165-170
U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances Miller David G	Jul/Aug 2015 Pg. 303-305
The Role of Drug Promotion in the Prescription of Hormone Replacement Therapy in the United States Stephenson Kenna, Jones William, Stephenson Douglas M M	May/Jun 2006 Pg. 175-183
The U.S. Food and Drug Administration Takes Aim at Compounded Thyroid Hormone Brunner Scott	Jan/Feb 2023 Pg. 22-23
Book Review: HRT: The Answers. A Concise Guide for Solving the Hormone Replacement Therapy Puzzle Reed-Kane Dana	Nov/Dec 2004 Pg. 412
U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs Allen Loyd V Jr	Nov/Dec 2015 Pg. 487-488
U.S. Food and Drug Administration List of Drugs NOT to be Used in Compounded Medications for Humans (The Negative List)	Nov/Dec 2016 Pg. 457-458
A Perspective on HRT for Women: Picking Up the Pieces After the Women's Health Initiative Trial - Part 1 Gillson George R, Zava David T	Jul/Aug 2003 Pg. 250-256
Hormone Therapy: It's Time for a Second Opinion Collins Joseph J, Ahlgrimm Maria	Mar/Apr 2008 Pg. 122-127
Menopausal Symptom Relief and Side Effects Experienced by Women Using Bioidentical Hormone Replacement Therapy and Synthetic Conjugated Equine Estrogen and/or Progestin Hormone Replacement Therapy, Part 1 Deleruyelle Laura J	Sep/Oct 2016 Pg. 359-364
U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies Yoch Doug	Mar/Apr 2017 Pg. 95-102
Safety Standards in Pharmaceutical Compounding, Part 3: Fire Safety Allen W Chris, Greeson Nicole MH, Mixon William	Nov/Dec 2020 Pg. 451-458
Return to Top